|  | FGFR3 mutations (nonsynonymous/indels) | FGFR3 fusion | ||||
---|---|---|---|---|---|---|---|
Variables | n = 389 | mutation -n = 308 (79%) | mutation + n = 81 (21%) | p value | fusion -n = 372 (96%) | fusion + n = 17 (4%) | p value |
Sex (%) | |||||||
 male | 306 (79) | 243 (79) | 63 (78) |  | 291 (78) | 15 (88) |  |
 female | 83 (21) | 65 (21) | 18 (22) | 0.83 | 81 (22) | 2 (12) | 0.29 |
Age (mean ± SD) | |||||||
 | 70 ± 11.2 | 69 ± 11.1 | 70 ± 11.5 | 0.52 | 70 ± 11.2 | 69 ± 10.6 | 0.82 |
Smoking history (%) | |||||||
 never | 132 (34) | 102 (33) | 30 (37) |  | 127 (34) | 5 (29) |  |
 past/current | 242 (62) | 193 (63) | 49 (60) |  | 231 (62) | 11 (65) |  |
 unnown | 15 (4) | 13 (4) | 2 (3) | 0.64 | 14 (4) | 1 (6) | 0.86 |
Clinical Stage (%) | |||||||
 cN0M0 | 315 (81) | 244 (79) | 71 (87) |  | 301 (81) | 14 (82) |  |
 cN1M0 | 51 (13) | 44 (14) | 7 (9) |  | 50 (13) | 1 (6) |  |
 cNxM1 | 23 (6) | 20 (7) | 3 (4) | 0.2 | 21 (6) | 2 (12) | 0.43 |
Muscle invasion (%) | |||||||
 NMIBC | 124 (32) | 75 (24) | 49 (61) |  | 115 (31) | 9 (53) |  |
 MIBC | 265 (68) | 233 (76) | 32 (39) |  < 0.001* | 257 (69) | 8 (47) | 0.06 |
Histological variants (%) | |||||||
 no | 345 (89) | 270 (88) | 75 (93) |  | 328 (88) | 17 (100) |  |
 yes | 44 (11) | 38 (12) | 6 (7) | 0.19 | 44 (12) | 0 (0.0) | 0.04* |
Concomittant CIS (%) | |||||||
 no | 333 (86) | 258 (84) | 75 (93) |  | 320 (86) | 13 (76) |  |
 yes | 56 (14) | 50 (16) | 6 (7) | 0.03* | 52 (14) | 4 (24) | 0.31 |
Pathological grade (WHO2004) | |||||||
 low | 40 (10) | 19 (6) | 21 (26) |  | 37 (10) | 3 (18) |  |
 high | 349 (90) | 289 (94) | 60 (74) |  < 0.001* | 335 (90) | 14 (82) | 0.35 |
Lymphovascular invasion | |||||||
 no | 179 (46) | 121 (39) | 58 (72) |  | 169 (45) | 10 (59) |  |
 yes | 210 (54) | 187 (61) | 23 (28) |  < 0.001* | 203 (55) | 7 (41) | 0.28 |
Median follow-up period | |||||||
  (months: [IQR]) | 31 [15, 44] | 29 [14, 42] | 38 [20, 45] |  | 31 [15, 42] | 47 [23, 55] |  |